Poseida Therapeutics stock (US74020J1025): Recent merger triggers corporate action

Poseida Therapeutics (PSTX) underwent a cash and stock merger on May 4, 2026, with shareholders receiving $9.00 and 1 share of PSTX^ per share, according to Robinhood's corporate actions tracker. The Nasdaq-listed biotech focuses on CAR-T therapies for cancer.

Poseida Therapeutics, a clinical-stage biotech firm developing CAR-T cell therapies for cancer, executed a cash and stock merger effective May 4, 2026. Shareholders received $9.0000 in cash plus 1.0000 shares of PSTX^ for each share of PSTX held, as detailed in Robinhood corporate actions tracker as of May 2026. This move impacts Nasdaq-listed shares (PSTX), making it relevant for US retail investors tracking biotech restructurings.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Poseida Therapeutics, Inc.
• Sector/industry: Biotechnology / CAR-T therapies
• Headquarters/country: San Diego, USA
• Core markets: Oncology treatments
• Key revenue drivers: Pipeline of cell and gene therapies
• Home exchange/listing venue: Nasdaq (PSTX)
• Trading currency: USD

Poseida Therapeutics: core business model

Poseida Therapeutics specializes in next-generation CAR-T therapies targeting solid tumors and hematologic cancers. The company leverages proprietary platforms like piggyBac DNA Delivery System and Cas-CLOVER site-specific gene editing to create allogeneic CAR-T products, aiming for off-the-shelf treatments, according to its official website as of 2026. Headquartered in San Diego, Poseida advances therapies through clinical trials, with a focus on scalability and reduced manufacturing costs.

Main revenue and product drivers for Poseida Therapeutics

Poseida's pipeline includes lead candidates like P-PSMA-101 for prostate cancer and P-MUC1C-ALLO for various solid tumors. Revenue potential stems from partnerships and milestone payments, though as a clinical-stage firm, it relies on funding and trial progress. The recent merger restructuring could support ongoing R&D, per corporate action details from May 2026.

Conclusion

The May 4, 2026, merger represents a key corporate event for Poseida Therapeutics, altering share structure amid its pursuit of innovative cancer therapies. US investors should monitor IR updates for post-merger details and pipeline advancements. Developments in biotech CAR-T space continue to draw attention given the sector's growth potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.